Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 187 Carcinoma, Non-Small-Cell Lung 85 Breast Neoplasms 66 Neoplasms 62 Ovarian Neoplasms 59 Glioblastoma 40 Carcinoma, Hepatocellular 36 Neoplasm Metastasis 32 Colonic Neoplasms 27 Carcinoma, Renal Cell 24 Fallopian Tube Neoplasms 23 Uterine Cervical Neoplasms 21 Rectal Neoplasms 17 Pancreatic Neoplasms 17 Lung Neoplasms 17 Stomach Neoplasms 15 Liver Neoplasms 15 Brain Neoplasms 14 Non-Squamous Non-Small Cell Lung Cancer 13 Endometrial Neoplasms 11 Recurrence 10 Glioma 10 Carcinoma, Ovarian Epithelial 10 Triple Negative Breast Neoplasms 9 Melanoma 9 Gastrointestinal Neoplasms 9 Advanced Solid Tumors 9 Solid Cancers 7 Peritoneal Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 7

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pan-tumor × Bevacizumab × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡